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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
The objective of this review is to assess the effects and safety of blood product transfusion strategies started in the first 24 hours after
injury for trauma patients of all ages with major bleeding.
B A C K G R O U N D
Description of the condition
Worldwide, trauma is one of the leading causes of death and dis-
ability among children and young adults aged 44 and under (Cap
2015). Approximately 40% of deaths from trauma are due to un-
controlled bleeding or its consequences (Frith 2010). Death from
exsanguination occurs early, with the majority of patients dying
within the first few hours after injury (Cripps 2013). Some pa-
tients are hypercoagulable after trauma, some have normal coag-
ulation parameters, and some are hypocoagulable. Approximately
one quarter of trauma patients with major bleeding develop a co-
agulopathy (abnormal clotting) known as acute traumatic coag-
ulopathy or trauma-induced coagulopathy (we will use the term
trauma-induced coagulopathy) soon after injury (Brohi 2003). In
patients with this coagulopathy, the ability of their blood to form
a clot is impaired. Coagulopathy in trauma is known to be associ-
ated with increased transfusion requirements, organ injury, sepsis,
critical care stays, and death (Cohen 2012; Frith 2010; MacLeod
2003; Maegele 2007).
Trauma-induced coagulopathy may be diagnosed by elevated lab-
oratory test results, such as prothrombin time (PT), international
normalised ratio (INR), or the activated partial thromboplastin
time (APTT). There is no consensus on the laboratory defini-
tion of trauma-induced coagulopathy. Two different ranges are
commonly used within the research and clinical literature: a PTr/
INR ratio of 1.2 and above (Frith 2010), and a PTr/INR ratio of
1.5 and above (Chin 2014). Using a global test of haemostasis,
trauma-induced coagulopathy has been defined as a reduction in
clot strength (amplitude), measured at five minutes (A5 ≤ 40 mm)
by rotational thromboelastometry (ROTEM (Hagemo 2015)). Al-
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though the mechanisms of trauma-induced coagulopathy are in-
completely understood, it is clear that it is a complex process that
involves clotting pathways, platelet and endothelial dysfunction,
and a rapid breakdown of clots (Curry 2012; Dobson 2015; Raza
2013; Rourke 2012).
If not adequately treated, trauma-induced coagulopathy worsens
during bleeding (Brohi 2003; Kahn 2014). In traumatic brain in-
jury, coagulopathy is associated with adverse outcomes. It has been
suggested that the release of a key protein, known as tissue factor,
plays a key role in the development of abnormal clotting. How
this compares to the coagulopathy in patients without traumatic
brain injury is beginning to be better understood (Maegele 2013).
Description of the intervention
Trauma patients who arrive at the hospital with major haemor-
rhage are treated with an approach known as damage control resus-
citation. This integrated approach has a primary aim of stopping
the bleeding. It focuses on: (1) diagnostic and treatment pathways
to identify and stop on-going bleeding, e.g. early surgery or inter-
ventional radiology, and (2) best supportive care, using a transfu-
sion strategy.
In the trauma setting, different strategies have been used to ad-
dress shock and deranged coagulation. These include transfusion
with different combinations or ratios of blood products, i.e. red
blood cells (RBCs), fresh frozen plasma (FFP), platelets, cryopre-
cipitate, whole blood, lyophilised platelets, lyophilised plasma, or
liquid plasma. These strategies have developed from an increased
understanding about the role that transfusion resuscitation may
play in treating and limiting this clotting abnormality (Borgman
2007).
Current approaches to resuscitation specify early delivery of blood
products without waiting for clotting results (empiric transfusion),
while avoiding colloid or crystalloid infusions, in an attempt to
prevent and immediately correct coagulopathy (Holcomb 2007).
To facilitate empiric transfusion, many hospitals use a major haem-
orrhage protocol, whereby a fixed ratio of blood products is deliv-
ered to the bedside in a major haemorrhage pack. Further blood
product administration is then guided by conventional hospital
laboratory clotting tests or viscoelastic haemostatic assays, such as
traditional thromboelastography (TEG) or ROTEM. Tranexamic
acid is routinely given to patients with traumatic haemorrhage, the
first dose administered within three hours of the injury (CRASH-2
trial 2010). In addition to transfusion strategies that use FFP to
red blood cell ratios higher than 1:2, some studies have explored
the use of more balanced platelet to red blood cell ratios, with the
result that some centres now advocate a 1:1 ratio. Early timing of
platelet transfusion may be important, as there is evidence of early
platelet dysfunction in major trauma (Wohlauer 2012).
There has also been recent recognition of the critical role of fib-
rinogen, one of the first clotting factors to decrease in major bleed-
ing from trauma. The main exogenous concentrated sources of
fibrinogen are cryoprecipitate and fibrinogen concentrate. Cryo-
precipitate is a pooled plasma product containing high concen-
trations of FVIII, fibrinogen, vWF, fibronectin and FXIII. Fib-
rinogen concentrate is a lyophilised product (reconstituted from
a powder) from pooled donors that has been subjected to viral
inactivation.
Logistical issues, such as blood product storage or shelf-life may
hinder timely administration of blood products. This has led to
interest in the use of lyophilised plasma and platelet products.
Advantages of lyophilised products include a stable shelf-life, ease
of use and storage, and a low volume for administration.
How the intervention might work
Traumatic haemorrhage results in decreased circulating volume,
loss of oxygen-carrying capacity, and coagulopathy. Restoring cir-
culating volume is key to oxygen delivery. Transfusion of red blood
cells improves oxygen carriage and contributes to restoration of
adequate circulating volume, but given alone, is also associated
with worsening coagulopathy (Brohi 2003). For patients in need
of massive transfusion of individual components, some argue that
fresh whole blood is the optimum transfusion product, since all
blood constituents are administered in physiological quantities.
The addition of FFP decreases further depletion of clotting fac-
tors, and provides the coagulation factors needed for clot forma-
tion and prevention of clot breakdown. Platelets promote clotting
by providing a surface on which the clotting process can occur,
and sticking together to form a platelet plug. Cryoprecipitate is
administered as a main source of fibrinogen (Rourke 2012). Fresh
frozen plasma also appears to stabilise the lining of the blood ves-
sels, to help form a stable clot (Torres 2013).
However, the administration of blood products is not without risk.
Red blood cell transfusion is an independent predictor of mor-
tality in victims of trauma, and reducing administration would
be ideal, not least because of the high cost of the product and its
limited availability. Concerns have also been raised about the ad-
verse effects of administering higher volumes of FFP and platelet
products. But at present, the published data do not provide clear
answers on the risks of adverse events with high volume transfu-
sion, which include multi-organ failure, sepsis, thrombosis (blood
clots), and acute respiratory distress syndrome (Curry 2012).
Why it is important to do this review
The global impact of injury is under appreciated. In 2010, trauma
accounted for 5.1 million more deaths than HIV-AIDS, TB, and
malaria combined (Norton 2013). Rapid haemorrhage control
and improved resuscitation techniques may lead to better out-
comes for patients.
Currently, there is no consensus on transfusion strategies for the
acute management of bleeding in trauma. Despite recent changes
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to the delivery of blood products in trauma and much research
effort in the area, there are few completed trials to determine the
optimal transfusion strategy of blood products in trauma, and to
examine the adverse effects of such strategies.
O B J E C T I V E S
The objective of this review is to assess the effects and safety of
blood product transfusion strategies started in the first 24 hours
after injury for trauma patients of all ages with major bleeding.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will consider randomised controlled trials that relate to the
early management of haemorrhage (within the first 24 hours of
injury) with blood products (red blood cells, whole blood, fresh
frozen plasma, platelets, cryoprecipitate, including lyophilised
plasma, lyophilised platelets, and liquid plasma) in injured pa-
tients. We will only include trials that were prospectively regis-
tered, unless the final report was published before 2010.
Types of participants
We will include adults and children (with no age restriction) with
major bleeding caused by trauma.
Patients with major bleeding will be defined as those with active
bleeding and shock, those who require activation of the major
haemorrhage protocol, or those predicted to bleed, using a scoring
system for haemorrhage in trauma, or as otherwise described by the
study authors. We will exclude trials that assessed isolated burns
injuries, due to the different mechanism of injury.
Types of interventions
A variety of transfusion strategies is currently used in trauma haem-
orrhage, but consensus is lacking. Interventions will be examining
different ways of using blood products (blood transfusion strate-
gies) in acute bleeding due to trauma. We will consider all trials
that are comparing two transfusion strategies, including the fol-
lowing examples:
• Goal-directed strategy of laboratory clotting tests versus
viscoelastic haemostatic assay
• Different ratios of blood products e.g. a transfusion strategy
with fresh frozen plasma (FFP), platelets, and red blood cells in a
1:1:1 unit ratio compared to FFP, platelets, and red blood cells in
a 1:1:2 ratio).
• Whole blood versus individual blood components
Each blood transfusion strategy must include at least one of:
red blood cells or a blood component (FFP, cryoprecipitate,
whole blood, platelets, lyophilised or liquid plasma, or lyophilised
platelets), and must not contain only recombinant or plasma de-
rived single factor, or multiple coagulation factor concentrates,
such as fibrinogen concentrate, prothrombin complex concen-
trate, and recombinant FVIIa, since these interventions are cov-
ered elsewhere (Fabes 2013). There is no standardised transfusion
strategy for major bleeding in trauma. The 2016 guidelines from
the National Institute for Health and Clinical Excellence (NICE)
recommend initial empirical transfusion of red cells and FFP in
a 1:1 ratio (NICE 2016). The 2016 European Trauma Society
Guidelines recommend transfusion to keep haemoglobin at 70
to 90 g/L, and FFP or fibrinogen replacement in patients with
massive bleeding; if further plasma is administered, an optimal
plasma to red blood cell ratio of at least 1:2 is suggested. The
European guidelines also suggest a threshold-based approach to
platelet transfusion (Rossaint 2016). Both guidelines recommend
starting transfusions within 24 hours of injury.
Examples of blood transfusion strategies for trauma patients with
major bleeding include:
• blood component transfusion guided by laboratory or
global haemostatic tests;
• FFP to platelets to red blood cells in 1:1:1 ratio;
• FFP to platelets to red blood cells in 1:1:2 ratio;
• FFP to red blood cells in 1:2 ratio;
• two pools of early cryoprecipitate, then FFP to red cells in
6:4 ratio;
• modified whole blood;
• individual or combination transfusion of any of the
following blood components: red cells, FFP, platelets,
cryoprecipitate, lyophilised plasma, lyophilised platelets, and
liquid plasma.
We will consider all trials, including placebo-controlled trials,
where the comparator is a non-blood component (e.g. fluid resus-
citation). An example of placebo-controlled trials might be stud-
ies evaluating blood products that are not the current standard,
e.g. early cryoprecipitate with empirical transfusion versus saline
placebo and empirical transfusion. We recognise that placebo-con-
trolled trials may be challenging for studies of blood components.
Types of outcome measures
Primary outcomes
• All-cause mortality at 24 hours;
• All-cause mortality at 30 days.
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Secondary outcomes
• Mortality due to haemorrhage within 24 hours.
• Time-to-anatomical haemostasis, as described in the study.
• Total thromboembolic events (arterial and venous) in the
first 30 days after injury.
• Transfusion requirements (number of units or volume of red
cells, FFP, Cryoprecipitate, and Platelets) in the first 24 hours.
• Degree of coagulopathy (defined as maximal change in
prothrombin time (PT) or INR between baseline and post
intervention). Post intervention will be defined as up to one hour
after the final blood product transfusion.
• Requirement for surgery or interventional procedure to
control bleeding in the first 24 hours after injury.
• Length of stay in intensive care.
Information size estimate
In a sample size estimate, we calculated we would need to pool
3000 patients to have a 90% chance of detecting a decrease in
the primary outcome measure of death at the 5% level of signifi-
cance (from 26% in the control group to 21% in the experimental
group).
Search methods for identification of studies
Electronic searches
We will search the following databases for randomised controlled
trials (RCTs):
• Cochrane Central Register of Controlled Trials
(CENTRAL, The Cochrane Library, current issue; Appendix 1);
• MEDLINE Ovid (1946 to present; Appendix 2);
• Embase Ovid (1974 to present; Appendix 3);
• PubMed (in-process and epublications ahead of print only;
Appendix 4);
• Transfusion Evidence Library (1950 to present; Appendix
5);
• Web of Science Conference Proceedings Citation Index -
Science (CPCI-S, 1990 to present; Appendix 6);
• ClinicalTrials.gov;
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP).
The Cochrane Injuries Group will search the two ongoing trial reg-
istries. We have listed the search strategies for the other databases
in the appendices. We will combine searches in MEDLINE and
Embase with adaptations of RCT filters suggested in Chapter 6
of the Cochrane Handbook for Systematic Reviews of Interventions
(Lefebvre 2011). We will not limit searches by language, year of
publication, or publication type.
We will report the number of papers retrieved, assessed, included,
and excluded in the review. We will seek translators for potential
reports published in languages other than English.
Searching other resources
We will handsearch the reference lists of included studies to iden-
tify further relevant studies, and contact lead authors of the in-
cluded studies to identify any unpublished material, missing data,
or information about ongoing studies.
Data collection and analysis
Selection of studies
One review author (CD) will initially screen all search results for
relevance against the eligibility criteria and discard all titles that
are clearly irrelevant. Two review authors (HW, NC) will indepen-
dently screen the remaining titles and abstracts. We will obtain the
full texts of reports that appear to be eligible, or of which we are
unsure, to determine their ultimate relevance. We will seek further
information from the trial authors when articles contain insuffi-
cient data to make a decision about eligibility. We will resolve dif-
ferences of opinion through discussion and consensus, and consult
with a third review author (SS) if necessary.
Data extraction and management
Two review authors (HW, JB) will independently extract data onto
study-specific data extraction forms. They will pilot the forms on
two relevant RCTs, and adjust the form as necessary after discus-
sion. Throughout the data extraction process, they will resolve any
disagreement by discussion with a third review author (NC). If
agreement cannot be reached, they will consult with a fourth au-
thor (SS).
The review authors will not be blinded to the names of authors,
institutions, journals, or outcomes of the trials. If considered rel-
evant, they will request copies of the trial protocols from the trial
authors.
Data will include:
1. Trial details: review author’s name; year; date of data
extraction; first author of study; author’s contact address (if
available); objectives of the trial; country of origin; clinical
setting; number of centres; recruitment dates; method of
sequence generation; allocation concealment; blinding (of
clinicians, participants, and outcome assessors); inclusion and
exclusion criteria; definition of major haemorrhage; definition of
coagulopathy; comparability of groups; length of follow-up; use
of intention-to-treat analysis; funding source.
2. Participant data: age; gender; mechanism of injury (blunt
or penetrating trauma); isolated traumatic brain injury;
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percentage of patients on anticoagulant or anti-platelet therapy;
Injury Severity Score (ISS); total number of participants
recruited; total number randomised; total number analysed for
endpoints; losses to follow-up and dropouts.
3. Interventions: nature of experimental and control
interventions; timing, dosage and route of intervention;
compliance to interventions; additional interventions given
including tranexamic acid.
4. Outcomes: primary and secondary outcomes; outcome
cutoffs; incomplete outcome data; conclusions reported.
Assessment of risk of bias in included studies
Two review authors will independently assess bias using the
Cochrane tool. To assess risk of bias, we will address the follow-
ing questions in the ’Risk of bias’ table for each included study
(Higgins 2011).
1. Was the allocation sequence adequately generated?
2. Was allocation adequately concealed?
3. Was knowledge of the allocated intervention adequately
prevented (i.e. blinded) throughout the study for participants,
study personnel, and outcome assessors?
4. Were incomplete outcome data adequately addressed for
the main outcome?
5. Are reports of the study free of selective outcome reporting?
We will report ’Risk of bias’ domains 2, 3, 4, and 5 separately
for each of the two main outcomes, and where data allow, for the
secondary outcomes.
We will categorise individual studies as being at low, high, or un-
clear overall risk of bias according to the following:
• low risk of bias - all domains were at low risk of bias
(plausible bias unlikely to seriously alter the results);
• unclear risk of bias - one or more domains had an unclear
risk of bias (plausible bias that raises some doubt about the
results); or
• high risk of bias - one or more domains were at high risk of
bias (plausible bias that seriously weakens confidence in the
results).
We anticipate that knowledge of the allocated intervention will
be difficult to blind from clinicians and participants. However,
we believe that it would be possible to blind knowledge of the
allocated intervention from outcome assessors. We will bear these
considerations in mind when assessing risk of bias for domain 3
above. We will record all quotes from studies separately from our
judgement in the ’Risk of bias’ table.
Measures of treatment effect
We will calculate risk ratios (RR) for dichotomous data outcomes
with 95% confidence intervals (CI). Where the number of ob-
served events is small (less than 5% of sample per group), and
where trials have balanced treatment groups, we will report the
Peto odds ratio (OR) with 95% CI (Deeks 2011). We will express
treatment effects for continuous data outcomes as mean differ-
ences (MD) with 95% CI; if the outcomes are measured using
different scales, we will use standardised mean differences (SMD)
with 95% CI.
Unit of analysis issues
We anticipate that the patient will be the unit of analysis.
We do not expect to encounter any cluster-randomised trials, but
if we do identify any, we will treat them in accordance with the
advice given in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). We will treat multi-arm trials in
accordance with the advice given in Chapter 16 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Dealing with missing data
We will attempt to contact the trial authors to obtain missing data
or to clarify unclear data. For each included study, we will record
the number of participants lost to follow-up. Where possible, we
will analyse data on an intention-to-treat basis, but if there are
missing data, we will present per-protocol analyses. Where stan-
dard deviations are not reported, we will try to determine these
from standard errors, confidence intervals, or exact P values.
Assessment of heterogeneity
We will use the I² statistic to quantify the possible degree of hetero-
geneity of treatment effects between trials. We will assume moder-
ate heterogeneity when the I² is higher than 50% and considerable
heterogeneity when it is higher than 80%. Due to the nature of
the studies, we expect moderate heterogeneity, therefore, in the
first instance, we will use a random-effects model. We will explore
potential causes of heterogeneity by sensitivity and subgroup anal-
ysis (Deeks 2011).
Assessment of reporting biases
Although every effort will be made to identify unpublished studies,
we will assess publication bias using funnel plots, provided there
are at least 10 studies included in each meta-analysis.
Data synthesis
If studies are considered sufficiently homogeneous, we will con-
duct a meta-analysis, according to Cochrane recommendations
(Deeks 2011). We will enter data into Review Manager 5 (Review
Manager 2014) for statistical analysis.
Where meta-analysis is feasible, we will use the random-effects
model for pooling the data. For dichotomous outcomes we will
use the Mantel-Haenszel method or the Peto method as neces-
sary, and the inverse variance method for continuous outcomes,
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according to the recommendations of Chapter 9 of the Cochrane
Handbook for Systematic Reviews of Interventions (Deeks 2011). If
heterogeneity is found to be above 80%, we will not perform a
meta-analysis, but will perform a qualitative analysis, grouping
similar transfusion strategies, and commenting on the results as a
narrative.
A network meta-analysis would not be appropriate due to issues
with transitivity.
Subgroup analysis and investigation of heterogeneity
If there are sufficient data, we will perform subgroup analyses to
see if there are significant differences in treatment effect:
1. Children versus adults for patients treated with the same
protocol (since different definitions of coagulopathy apply).
2. Studies of older adults (over 65 years of age) compared with
younger adults, since older patients are more likely to have co-
morbidities, such as cardiovascular disease, and possible
differences in efficacy of transfusion interventions.
3. Studies of patients with traumatic brain injury, in view of
the effect of a central nervous system injury on coagulopathy, and
the possible differences in efficacy of interventions in this group.
If we identify any other subgroup effects, we will clearly identify
them as hypothesis-generating. We will use the test for subgroup
differences provided in Review Manager 5, to establish whether the
subgroups are statistically significantly different from one another.
Sensitivity analysis
If data are available, we will perform sensitivity analyses to explore
aspects of trial and review methodology. These will include ex-
ploring the effects of removing trials at high or unclear risk of the
following domains of bias:
1. selection bias (reflecting lack of confirmation of random
sequence generation and allocation concealment);
2. detection bias (reflecting lack of assessor blinding);
3. attrition bias, such as from high levels of missing data.
We will perform trial sequential analysis to explore the robustness
of any statistically significant effects found for the review’s primary
outcomes that did not meet the expected sample size.
’Summary of Findings’ table
We will use GRADEpro GDT software and the GRADE approach
to create a ’Summary of findings’ table, as suggested in Chapters
11 and 12 of the Cochrane Handbook for Systematic Reviews of
Interventions (GRADEpro GDT; Schünemann 2011). We will
provide rationale for the figure used to calculate the assumed risk
in a footnote. We will use the GRADE approach to rate the quality
of the evidence as ’high’, ’moderate’, ’low’, or ’very low’, using the
five GRADE considerations below. We will provide the rationale
for downgrading in a footnote.
• Risk of bias: serious or very serious
• Inconsistency: serious or very serious
• Indirectness: serious or very serious
• Imprecision: serious or very serious
• Publication bias: serious or very serious
We will present the following outcomes in a separate ’summary of
findings’ table for each comparison. The following five outcomes
will be included because we consider these to be most clinically
important and useful for review users.
• All-cause mortality at 24 hours
• All-cause mortality at 30 days
• Time-to-anatomical haemostasis
• Transfusion requirements - total number of red cell units
during first 24 hours
• Total thromboembolic events in the first 30 days
A C K N O W L E D G E M E N T S
We thank the editorial base of the Cochrane Injuries Review
Group.
R E F E R E N C E S
Additional references
Borgman 2007
Borgman MA, Spinella PC, Perkins JG, Grathwohl KW,
Repine T, Beekley AC, et al. The ratio of blood products
transfused affects the mortality in patients receiving massive
transfusions at a combat support hospital. Journal of
Trauma: Injury, Infection, and Critical Care 2007;63:805-
13. [DOI: 10.1097/TA.0b013e3181271ba3]
Brohi 2003
Brohi K, Singh J, Heron M, Coats T. Acute traumatic
coagulopathy. Journal of Trauma: Injury, Infection, and
Critical Care 2003;54(6):1127–30. [DOI: 10.1097/
01.TA.0000069184.82147.06]
Cap 2015
Cap A, Hunt BJ. The pathogenesis of traumatic
coagulopathy. Anaesthesia 2015;70(Suppl 1):96–101.
[DOI: 10.1111/anae.12914]
Chin 2014
Chin TL, Moore EE, Moore HB, Gonzalez E, Chapman
MP, Stringham JR, et al. A principal component analysis of
postinjury viscoelastic assays: clotting factor depletion versus
fibrinolysis. Surgery 2014;156(3):570–7. [PUBMED:
24962188]
6Strategies for use of blood products for major bleeding in trauma (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cohen 2012
Cohen MJ, Call M, Nelson M, Calfee CS, Esmon CT,
Brohi K, et al. Critical role of activated protein C in early
coagulopathy and later organ failure, infection and death
in trauma patients. Annals of Surgery 2012;255(2):379-85.
[DOI: 10.1097/SLA.0b013e318235d9e6]
CRASH-2 trial 2010
CRASH-2 trial collaborators. Effects of tranexamic acid on
death, vascular occlusive events, and blood transfusion in
trauma patients with significant haemorrhage (CRASH-2):
a randomised, placebo-controlled trial. Lancet 2010;376
(9734):23-32. [DOI: 10.1016/S0140-6736(10)60835-5]
Cripps 2013
Cripps MW, Kutcher ME, Daley A, McCreery RC,
Greenberg MD, Cachola LM, et al. Cause and timing of
death in massively transfused trauma patients. Journal of
Trauma and Acute Care Surgery 2013;75:S255–62. [DOI:
10.1097/TA.0b013e31829a24b4]
Curry 2012
Curry NS, Davenport RA, Hunt BJ, Stanworth SJ.
Transfusion strategies for traumatic coagulopathy.
Transfusion Reviews 2012;26(5):223–32. [DOI: 10.1016/
j.blre.2012.06.004]
Deeks 2011
Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9:
Analysing data and undertaking meta-analyses. In: Higgins
JPT, Green S (editors). Cochrane Handbook for Systematic
Reviews of Interventions Version 5.1.0 (updated March
2011). The Cochrane Collaboration, 2011. Available from
www.handbook.cochrane.org.
Dobson 2015
Dobson GP, Letson HL, Sharma R, Sheppard FR, Cap
AP. Mechanisms of early trauma-induced coagulopathy:
the clot thickens or not?. Journal of Trauma and Acute
Care Surgery 2015;79(2):301–9. [DOI: 10.1097/
TA.0000000000000729]
Fabes 2013
Fabes J, Barker G, Simons G, Curry N, Brunskill SJ,
Doree C, et al. Pro-coagulant haemostatic factors for the
prevention and treatment of bleeding in patients without
haemophilia. Cochrane Database of Systematic Reviews 2013,
Issue 7. [DOI: 10.1002/14651858.CD010649]
Frith 2010
Frith D, Goslings JC, Gaardner C, Maegele M, Cohen MJ,
Allard S, et al. Definition and drivers of acute traumatic
coagulopathy: clinical and experimental investigations.
Journal of Thrombosis and Haemostasis 2010;8:1919–25.
[DOI: 10.1111/j.1538-7836.2010.03945.x]
GRADEpro GDT [Computer program]
GRADE Working Group, McMaster University.
GRADEpro GDT. Version (assessed 19 November 2016).
Hamilton (ON): GRADE Working Group, McMaster
University, 2014.
Hagemo 2015
Hagemo JS, Christiaans SC, Stanworth SJ, Brohi
K, Johansson PI, Goslings JC, et al. Detection of
acute traumatic coagulopathy and massive transfusion
requirements by means of rotational thromboelastometry:
an international prospective validation study. Critical Care
2015;19(1):97.
Higgins 2011
Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting
studies and collecting data. In: Higgins JPT, Green S
(editors). Cochrane Handbook for Systematic Reviews
of Interventions Version 5.1.0 (updated March 2011).
The Cochrane Collaboration, 2011. Available from
www.handbook.cochrane.org.
Holcomb 2007
Holcomb JB, Jenkins D, Rhee P, Johannigman J, Mahoney
P, Mehta S, et al. Damage control resuscitation: directly
addressing the early coagulopathy of trauma. Journal of
Trauma: Injury, Infection, and Critical Care 2007;62(2):
307–10. [DOI: 10.1097/TA.0b013e3180324124]
Kahn 2014
Khan S, Brohi K, Chana M, Raza I, Stanworth S, Gaarder
C, et al. International Trauma Research Network
(INTRN). Hemostatic resuscitation is neither hemostatic
nor resuscitative in trauma hemorrhage. Journal of Trauma
and Acute Care Surgery 2014;76(3):561–7. [DOI: 10.1097/
TA.0000000000000146]
Lefebvre 2011
Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching
for studies. In: Higgins JPT, Green S (editors). Cochrane
Handbook for Systematic Reviews of Interventions Version
5.1.0 (updated March 2011). The Cochrane Collaboration,
2011. Available from www.handbook.cochrane.org.
MacLeod 2003
MacLeod JB, Lynn M, McKenney MG, Cohn SM, Murtha
M. Early coagulopathy predicts mortality in trauma. Journal
of Trauma: Injury, Infection, and Critical Care 2003;55:
39–44. [DOI: 10.1097/01.TA.0000075338.21177.EF]
Maegele 2007
Maegele M, Lefering R, Yucel N, Tjardes T, Rixen D,
Paffrath T, et al. Early coagulopathy in multiple injury:
an analysis from the German Trauma Registry on 8724
patients. Injury 2007;38(3):298-304. [DOI: 10.1016/
j.injury.2006.10.003]
Maegele 2013
Maegele M. Coagulopathy after traumatic brain injury:
incidence, pathogenesis and treatment options. Transfusion
2013;53:28S–37S. [DOI: 10.1111/trf.12033]
NICE 2016
National Institute for Health and Clinical Excellence
(NICE). Major trauma: assessment and initial management
(NG39). www.nice.org.uk/guidance/ng39 (accessed 8 April
2016).
7Strategies for use of blood products for major bleeding in trauma (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Norton 2013
Norton R, Kobusingye O. Injuries. New England Journal
of Medicine 2013;368(18):1723–30. [DOI: 10.1056/
NEJMra1109343]
Raza 2013
Raza I, Davenport R, Rourke C, Platton S, Manson J,
Spoors C, et al. The incidence and magnitude of fibrinolytic
activation in trauma patients. Journal of Thrombosis
and Haemostasis 2013;11(2):307–14. [DOI: 10.1111/
jth.12078]
Review Manager 2014 [Computer program]
Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager 5 (RevMan 5). Version 5.3. Copenhagen:
Nordic Cochrane Centre, The Cochrane Collaboration,
2014.
Rossaint 2016
Rossaint R, Bouillon B, Cerny V, Coats TJ, Duranteau J,
Fernández-Mondéjar E, et al. The European guideline on
management of major bleeding and coagulopathy following
trauma: fourth edition. Critical Care 2016;20:100. [DOI:
10.1186/s13054-016-1265-x]
Rourke 2012
Rourke C, Curry N, Khan S, Taylor R, Raza I, Davenport R,
et al. Fibrinogen levels during trauma hemorrhage, response
to replacement therapy, and association with patient
outcomes. Journal of Thrombosis and Haemostasis 2012;10
(7):1342–51. [DOI: 10.1111/j.1538-7836.2012.04752.x]
Schünemann 2011
Schünemann HJ, Oxman AD, Higgins JPT, Vist GE,
Glasziou P, Guyatt GH. Chapter 11: Presenting results
and ’Summary of findings’ tables. In: Higgins JPT,
Green S (editors). Cochrane Handbook for Systematic
Reviews of Interventions Version 5.1.0 (updated March
2011). The Cochrane Collaboration, 2011. Available from
www.handbook.cochrane.org.
Torres 2013
Torres LN, Sondeen JL, Ji L, Dubick MA, Filho IT.
Evaluation of resuscitation fluids on endothelial glycocalyx,
venular blood flow, and coagulation function after
hemorrhagic shock in rats. Journal of Trauma and
Acute Care Surgery 2013;75:759–66. [DOI: 10.1097/
TA.0b013e3182a92514]
Wohlauer 2012
Wohlauer MV, Moore EE, Thomas S, Sauaia A, Evans E,
Harr J, et al. Early platelet dysfunction: an unrecognized
role in the acute coagulopathy of trauma. Journal of the
American College of Surgeons 2012;214(5):739–46. [DOI:
10.1016/j.jamcollsurg.2012.01.050]
∗ Indicates the major publication for the study
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Multiple Trauma] this term only
#2 MeSH descriptor: [Shock, Hemorrhagic] this term only
#3 MeSH descriptor: [Shock, Traumatic] explode all trees
#4 MeSH descriptor: [Trauma Severity Indices] explode all trees
#5 MeSH descriptor: [Trauma Centers] explode all trees
#6 MeSH descriptor: [Accidents] explode all trees
#7 MeSH descriptor: [Traumatology] this term only
#8 (stabb* or shooting or gunshot* or blast* or bomb* or explosi* or disaster* or casualt* or catastroph* or combat* or battlefield*):ti
#9 ((uncontroll* or ongoing or massive* or major or shock* or critical* or serious* or severe* or life-threatening* or trauma* or pelvic or
pelvis or abdominal* or arterial* or catastrophic* or control* or manag*) near/3 (haemorrhag* or hemorrhag* or bleed* or bloodloss*
or blood loss*))
#10 ((trauma* or injur*) near/3 (penetrating or blunt or multip*))
#11 (trauma* or combat* or gunshot* or blast* or battle*) near/2 surg*
#12 (trauma* or injur* or accident* or wound*) near/3 (critical* or massive* or major or serious* or severe* or life-threatening* or
coagulopath* or coagulat*)
#13 (injur* or wound*) near/3 (lacerat* or crush* or stab* or penetrating or blunt)
#14 (polytrauma* or “hypotensive resuscitation” or “hypovolemic shock” or “hypovolaemic shock”)
#15 (trauma* or exsanguin* or hypovolemi* or hypovolaemi* or coagulopath* or (abnormal* near/2 coagulation) or hyperfibrinolysis):
ti
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#16 MeSH descriptor: [Military Medicine] explode all trees
#17 MeSH descriptor: [Amputation, Traumatic] this term only
#18 MeSH descriptor: [Blast Injuries] this term only
#19 MeSH descriptor: [Rupture] explode all trees
#20 MeSH descriptor: [Wounds, Penetrating] explode all trees
#21 MeSH descriptor: [Lacerations] explode all trees
#22 MeSH descriptor: [Resuscitation] this term only
#23 MeSH descriptor: [Femoral Fractures] explode all trees
#24 ((hip* or pelvi* or femoral or femur) near/2 fracture*):ti
#25 MeSH descriptor: [Craniocerebral Trauma] explode all trees
#26 ((head or brain or cerebrocranial* or cranial* or craniocerebral* or cerebral or intracranial* or intra-cranial* or intracortical* or
intra-cortical* or subcortical* or sub-cortical* or intraventricul* or intra-ventricular* or periventricular* or peri-ventricular* or cerebell*
or cerebrum or corpus callosum or posterior fossa or hemispher*) near/5 (trauma* or injur* or wound*)):ti
#27 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #
20 or #21 or #22 or #23 or #24 or #25 or #26
#28 MeSH descriptor: [Blood Transfusion] this term only
#29 MeSH descriptor: [Blood Component Transfusion] explode all trees
#30 (RBC* or “red cell” or “red cells” or “red blood cell” or “red blood cells” or platelet* or FFP or cryoprecipitate or transfus* or
pretransfus* or posttransfus* or retransfus* or hypertransfus*):ti
#31 ((RBC* or “red cell” or “red cells” or “red blood cell” or “red blood cells” or platelet* or plasma or FFP or “whole blood” or
cryoprecipitate) near/6 (transfus* or pretransfus* or posttransfus* or retransfus* or hypertransfus*)):ab
#32 (“liquid plasma” or “fresh plasma” or “frozen plasma” or “cryopreserved plasma” or octaplas or “thawed plasma” or “platelet
concentrate*” or “cold-storage platelets” or “rehydrated platelets” or “fresh whole blood”)
#33 ((lyophili?ed or freeze-dried) near/3 (plasma or platelet*))
#34 (“blood product*” or “blood component*” or “blood management” or “blood therapy” or “blood replacement therapy”)
#35 (blood near/2 (storage or age or new* or old* or fresh* or stored)):ti
#36 ((massive* or major) near/3 transfus*):ab
#37 #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36
#38 #27 and #37
#39 MeSH descriptor: [Thrombelastography] explode all trees
#40 (thrombo-elastogra* or thrombelastogra* or thrombelasto-gra* or thromboelastogra* or TEG or ROTEM or ROTEG or haemo-
scope* or hemoscope* or haemonetics or hemonectics or EXTEM or INTEM or FIBTEM or HEPTEM or APTEM or thrombo-
elastomet* or thrombelastomet* or thromboelastomet* or Sonoclot or sono-clot)
#41 ((thromb* near/2 (elastogra* or elasto-gra* or elastom*)) or (rotational near/2 (thrombelast* or thromboelast*)))
#42 (viscoelastic or visco-elastic) and (detect* or coagulation or haemostatic or hemostatic)
#43 whole blood hemosta* system* or whole blood haemosta* system*
#44 #39 or #40 or #41 or #42 or #43
#45 #27 and #44
#46 #38 or #45
Appendix 2. MEDLINE Ovid search strategy
1. BLOOD TRANSFUSION/
2. exp BLOOD COMPONENT TRANSFUSION/
3. (transfus* or pretransfus* or posttransfus* or retransfus* or hypertransfus* or RBC* or red cell* or red blood cell* or platelet* or FFP
or cryoprecipitate).ti.
4. (blood product* or blood component* or blood management or blood therapy or blood replacement therapy).tw,kf.
5. (blood adj2 (storage or age or new* or old* or fresh* or stored)).ti,kf.
6. ((RBC* or red cell* or red blood cell* or platelet* or plasma or FFP or whole blood or cryoprecipitate) adj6 (transfus* or pretransfus*
or posttransfus* or retransfus* or hypertransfus*)).ab,kf.
7. (liquid plasma or fresh plasma or frozen plasma or cryopreserved plasma or thawed plasma or octaplas or platelet concentrate* or
cold-storage platelets or rehydrated platelets or fresh whole blood).tw,kf.
9Strategies for use of blood products for major bleeding in trauma (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
8. ((lyophili?ed or freeze-dried) adj3 (plasma or platelet*)).tw,kf.
9. ((massive* or major) adj3 transfus*).ab,kf.
10. or/1-9
11. exp Multiple Trauma/
12. Shock, Hemorrhagic/
13. exp Shock, Traumatic/






20. exp Crush Syndrome/
21. exp *Rupture/
22. exp *Wounds, Penetrating/
23. *Lacerations/
24. *Resuscitation/
25. (trauma* or exsanguin* or hypovolemi* or hypovolaemi* or coagulopath* or (abnormal* adj2 coagulation) or hyperfibrinolysis).ti.
26. (polytrauma* or hypotensive resuscitation or hypovolemic shock or hypovolaemic shock).tw,kf.
27. ((uncontroll* or ongoing or massive* or major or shock* or critical* or serious* or severe* or life-threatening* or trauma* or pelvic or
pelvis or abdominal* or arterial* or catastrophic* or control* or management) adj3 (haemorrhag* or hemorrhag* or bleed* or bloodloss*
or blood loss*)).tw,kf.
28. ((trauma* or injur* or accident* or wound*) adj3 (critical* or massive* or serious* or severe* or life-threatening* or coagulopath*
or coagulat*)).tw,kf.
29. ((trauma* or injur*) adj3 (penetrating or blunt or multip*)).tw,kf.
30. ((injur* or wound*) adj3 (lacerat* or stab* or crush* or penetrating or blunt)).tw,kf.
31. (stabb* or shooting or gunshot* or blast* or bomb* or explosi* or disaster* or casualt* or catastroph* or combat* or battlefield*).ti,kf.
32. ((trauma* or combat* or gunshot* or blast* or battle*) adj2 surger*).tw,kf.
33. exp *Femoral Fractures/ or ((pelvi* or femoral* or femur* or hip*) adj2 fracture*).ti,kf.
34. exp Craniocerebral Trauma/
35. ((head or brain or cerebrocranial* or cranial* or craniocerebral* or cerebral or intracranial* or intra-cranial* or intracortical* or
intra-cortical* or subcortical* or sub-cortical* or intraventricul* or intra-ventricular* or periventricular* or peri-ventricular* or cerebell*
or cerebrum or corpus callosum or posterior fossa or hemispher*) adj5 (trauma* or injur* or wound*)).ti,kf.
36. or/11-35
37. Thrombelastography/
39. (TEG or ROTEM or ROTEG).tw,kf.
40. (thromb* adj2 (elastogra* or elasto-gra*)).tw,kf.
41. (haemoscope* or hemoscope* or haemonetics or hemonectics).tw,kf.
42. whole blood h?emosta* system*.tw,kf.
43. (EXTEM or INTEM or FIBTEM or HEPTEM or APTEM).tw,kf.
44. (thrombo-elastomet* or thrombelastomet* or thromboelastomet*).tw,kf.
45. ((thromb* adj2 elasto?m*) or (rotational adj2 thromb?elast*)).tw,kf.
46. (Sonoclot or sono-clot).tw,kf.
47. ((viscoelastic or visco-elastic) adj5 (detect* or coagulation or haemostatic or hemostatic) adj5 (system* or process or test or tests or
analyz* or analys* or assay* or device* or measurement*)).tw,kf.
48. or/37-47
49. (10 or 48) and 36
50. randomized controlled trial.pt.
51. controlled clinical trial.pt.
52. (randomi* or trial).tw,kf.
53. (placebo or randomly or groups).ab.
54. clinical trials as topic.sh.
55. or/50-54
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56. (ANIMALS/ or exp ANIMAL EXPERIMENTATION/ or exp MODELS, ANIMAL/) not HUMANS/
57. 55 not 56
58. 49 and 57
Appendix 3. Embase Ovid search strategy
1. exp Blood Component Therapy/
2. Blood Transfusion/
3. ((RBC* or red cell* or red blood cell* or platelet* or plasma or FFP or whole blood or cryoprecipitate) adj6 (transfus* or pretransfus*
or posttransfus* or retransfus* or hypertransfus*)).ab.
4. (liquid plasma or fresh plasma or frozen plasma or platelet concentrate* or cold-storage platelets or rehydrated platelets or fresh whole
blood).tw.
5. ((lyophili?ed or freeze-dried) adj3 (plasma or platelet*)).tw.
6. (transfus* or pretransfus* or posttransfus* or retransfus* or hypertransfus* or RBC* or red cell* or red blood cell* or platelet* or
plasma or FFP or cryoprecipitate).ti.
7. (blood product* or blood component* or blood management or blood therapy or blood replacement therapy).tw.
8. (blood adj2 (storage or age or new* or old* or fresh* or stored)).ti.
9. ((massive* or major) adj3 transfus*).ab.
10. or/1-9
11. Multiple Trauma/
12. Exsanguination/ or Hemorrhagic Hypotension/ or Hemorrhagic Shock/
13. exp Injury Scale/
14. exp Traumatology/
15. Battle Injury/ or Blast Injury/ or Blunt Trauma/ or Crush Trauma/ or Traumatic Amputation/
16. Military Medicine/ or Gunshot Injury/ or Missile Wound/ or Stab Wound/ or Wound Hemorrhage/
17. ((uncontroll* or ongoing or massive* or major or shock* or critical* or serious* or severe* or life-threatening* or trauma* or pelvic or
pelvis or abdominal* or arterial* or catastrophic* or control* or management) adj3 (haemorrhag* or hemorrhag* or bleed* or bloodloss*
or blood loss*)).ti.
18. (polytrauma* or hypotensive resuscitation or hypovolemic shock or hypovolaemic shock or ((trauma* or injur*) adj3 (penetrating
or blunt or multip*))).tw.
19. (trauma* or exsanguin* or hypovolemi* or hypovolaemi* or coagulopath* or (abnormal* adj2 coagulation) or hyperfibrinolysis).ti.
20. ((trauma* or injur* or accident* or wound*) adj3 (critical* or massive* or serious* or severe* or life-threatening* or coagulopath*
or coagulat*)).tw.
21. ((injur* or wound*) adj3 (lacerat* or crush* or penetrating or blunt)).ti.
22. (stabb* or shooting or gunshot* or blast* or bomb* or explosi* or disaster* or casualt* or catastroph* or combat* or battlefield*).ti.
23. (trauma surger* or combat surger* or ((gunshot* or blast* or battle*) adj2 surger*)).tw.
24. exp *Hip Fracture/ or ((femoral* or femur* or hip* or pelvi*) adj2 fracture*).ti.
25. exp *“Head and Neck Injury”/
26. ((head or brain or cerebrocranial* or cranial* or craniocerebral* or cerebral or intracranial* or intra-cranial* or intracortical* or
intra-cortical* or subcortical* or sub-cortical* or intraventricul* or intra-ventricular* or periventricular* or peri-ventricular* or cerebell*
or cerebrum or corpus callosum or posterior fossa or hemispher*) adj5 (trauma* or injur* or wound*)).ti.
27. blood clotting disorder/ and trauma*.mp.
28. or/11-27
29. 10 and 28
30. Thrombelastography/
31. (thrombo-elastogra* or thrombelastogra* or thrombelasto-gra* or thromboelastogra* or TEG).tw.
32. (thromb* adj2 (elastogra* or elasto-gra*)).tw.
33. (haemoscope* or hemoscope* or haemonetics or hemonectics).tw.
34. whole blood h?emosta* system*.tw.
35. (ROTEM or ROTEG).tw.
36. (thrombo-elastomet* or thrombelastomet* or thromboelastomet*).tw.
37. ((thromb* adj2 elasto?m*) or (rotational adj2 thrombelast*) or “TEM international”).tw.
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38. (Sonoclot or sono-clot).tw.
39. ((viscoelastic or visco-elastic) and (detect* or coagulation) and (system* or process or test or tests or analyz* or analys* or assay* or
device* or measurement*)).tw.
40. or/30-39
41. 28 and 40
42. 29 or 41
43. crossover-procedure/ or double-blind procedure/ or randomized controlled trial/ or single-blind procedure/
44. (random* or factorial* or crossover* or cross over* or cross-over* or placebo* or doubl* blind* or singl* blind* or assign* or allocat*
or volunteer*).mp.
45. or/43-44
46. exp animal experiment/ not (exp human experiment/ or human/)
47. 45 not 46
48. 42 and 47
49. limit 48 to embase
Appendix 4. PubMed search strategy (in-process/epublications only)
#1 trauma[TI] OR traumatic*[TI] OR exsanguin*[TI] OR hypovolemi*[TI] OR hypovolaemi*[TI] OR stab[TI] OR stabb*[TI] OR
shooting[TI] OR gunshot*[TI] OR blast[TI] OR bomb*[TI] OR explosi*[TI] OR disaster*[TI] OR casualt*[TI] OR catastroph*[TI]
OR combat*[TI] OR battlefield*[TI] OR coagulopath*[TI]
#2 ((uncontroll*[TI] OR ongoing[TI] OR massive*[TI] OR major[TI] OR shock*[TI] OR critical*[TI] OR serious*[TI] OR se-
vere*[TI] OR life-threatening*[TI] OR pelvic[TI] OR pelvis[TI] OR abdominal*[TI] OR arterial*[TI] OR catastrophic*[TI] OR
control*[TI] OR manag*[TI]) AND (haemorrhag*[TI] OR hemorrhag*[TI] OR bleed*[TI] OR bloodloss*[TI] OR blood loss*[TI]))
#3 “critical injury”[TIAB] OR “critical injuries”[TIAB] OR “critically injured”[TIAB] OR “serious injury”[TIAB] OR “serious in-
juries”[TIAB] OR “seriously injured”[TIAB] OR “severe injury”[TIAB] OR “severe injuries”[TIAB] OR “severely injured”[TIAB] OR
“life-threatening injuries”[TIAB] OR “life-threateningly injured” OR “penetrating injury”[TIAB] OR “penetrating injuries”[TIAB]
OR “blunt injury”[TIAB] OR “multiple injuries”[TIAB] OR “multiply injured”[TIAB]
#4 ((trauma[TIAB] OR traumatic*[TIAB] OR combat*[TIAB] OR gunshot*[TIAB] OR blast[TIAB] OR battle*[TIAB]) AND
(surgery[TIAB] OR surgical*[TIAB] OR coagulopath* OR coagulat*[TIAB]))
#5 polytrauma*[TIAB] OR “hypotensive resuscitation”[TIAB] OR “hypovolemic shock”[TIAB] OR “hypovolaemic shock”[TIAB]
#6 (hip*[TI] OR pelvi*[TI] OR femoral[TI] OR femur[TI]) AND fracture*[TI]
#7 ((head[TI] OR brain[TI] OR cerebrocranial*[TI] OR cranial*[TI] OR craniocerebral*[TI] OR cerebral[TI] OR intracranial*[TI]
OR intra-cranial*[TI] OR intracortical*[TI] OR intra-cortical*[TI] OR subcortical*[TI] OR sub-cortical*[TI] OR intraventricul*[TI]
OR intra-ventricular*[TI] OR periventricular*[TI] OR peri-ventricular*[TI] OR cerebell*[TI] OR cerebrum[TI] OR corpus callo-
sum[TI] OR posterior fossa[TI] OR hemispher*[TI]) AND (trauma*[TI] OR injur*[TI] OR wound*[TI]))
#8 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7
#9 (thrombo-elastogra* OR thrombelastogra* OR thrombelasto-gra* OR thromboelastogra* OR TEG OR ROTEM OR ROTEG
OR haemoscope* OR hemoscope* OR haemonetics OR hemonetics OR EXTEM OR INTEM OR FIBTEM OR HEPTEM OR
APTEM OR thrombo-elastomet* OR thrombelastomet* OR thromboelastomet* OR Sonoclot OR sono-clot)
#10 (thromb* AND elastom*) OR (rotational AND (thromboelast* OR thrombelast*))
#11 ((viscoelastic OR visco-elastic) AND (detect* OR coagulation OR haemostatic OR hemostatic) AND (system* OR process OR
test OR tests OR analyz* OR analys* OR assay* OR device* OR measurement*))
#12 whole blood hemosta* system* OR whole blood haemostat* system*
#13 RBC*[TI] OR “red cell”[TI] OR “red cells”[TI] OR “red blood cell”[TI] OR “red blood cells”[TI] OR platelet*[TI] OR FFP[TI]
OR cryoprecipitate[TI] OR transfus*[TI] OR pretransfus*[TI] OR posttransfus*[TI] OR retransfus*[TI] OR hypertransfus*[TI]
#14 ((RBC*[TIAB] OR “red cell”[TIAB] OR “red cells”[TIAB] OR “red blood cell”[TIAB] OR “red blood cells”[TIAB] OR
platelet*[TIAB] OR plasma[TIAB] OR FFP[TIAB] OR “whole blood”[TIAB] OR cryoprecipitate[TIAB]) AND (transfus*[TIAB]
OR pretransfus*[TIAB] OR posttransfus*[TIAB] OR retransfus*[TIAB] OR hypertransfus*[TIAB]))
#15 (“liquid plasma” OR “fresh plasma” OR “frozen plasma” OR “cryopreserved plasma” OR octaplas OR “thawed plasma” OR
“platelet concentrate*” OR “cold-storage platelets” OR “rehydrated platelets” OR “fresh whole blood”)
#16 ((lyophilized OR lyphilised OR freeze-dried) AND (plasma OR platelet*))
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#17 (“blood product” OR “blood products” OR “blood component” OR “blood components” OR “blood management” OR “blood
therapy” OR “blood replacement therapy”)
#18 (blood[TI] AND (storage[TI] OR age[TI] OR new*[TI] OR old*[TI] OR fresh*[TI] OR stored[TI]))
#19 “massively transfused”[TIAB] OR “massive transfusion”[TIAB] OR “massive transfusions”[TIAB] OR “major transfusion”[TIAB]
OR “major transfusions”[TIAB]
#20 #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19
#21 #8 AND #20
#22 (random* OR blind* OR “control group” OR placebo* OR controlled OR groups OR trial*) AND (publisher[sb] OR inprocess[sb]
OR pubmednotmedline[sb])
#23 #21 AND #22
Appendix 5. Transfusion Evidence Library search strategy
Clinical Specialty: Trauma
Appendix 6. Web of Science CPCI-S search strategy
#1 TI=(RBC* OR “red cell” OR “red cells” OR “red blood cell” OR “red blood cells” OR platelet* OR FFP OR cryoprecipitate OR
transfus* OR pretransfus* OR posttransfus* OR retransfus* OR hypertransfus*)
#2 TS=(transfus* OR pretransfus* OR posttransfus* OR retransfus* OR hypertransfus* OR “liquid plasma” OR “fresh plasma” OR
“frozen plasma” OR “cryopreserved plasma” OR octaplas OR “thawed plasma” OR “platelet concentrate” OR “platelet concentrates” OR
“cold-storage platelets” OR “rehydrated platelets” OR “whole blood” OR “massive transfusion” OR “massively transfused” OR “major
transfusion” OR “lyophilized plasma” OR “lyophilised plasma” OR “freeze-dried plasma” OR “lyophilized platelets” OR “lyophilised
platelets” OR “freeze-dried platelets” OR “blood product*” OR “blood component*” OR “blood management” OR “blood therapy”
OR “blood replacement therapy”)
#3 TS=((thrombo-elastogra* OR thrombelastogra* OR thrombelasto-gra* OR thromboelastogra* OR TEG OR ROTEM OR ROTEG
OR haemoscope* OR hemoscope* OR haemonetics OR hemonectics OR EXTEM OR INTEM OR FIBTEM OR HEPTEM OR
APTEM OR thrombo-elastomet* OR thrombelastomet* OR thromboelastomet* OR Sonoclot OR sono-clot))
#4 TS=((thromb* AND elastom*) OR (rotational AND (thromboelast* OR thrombelast*)))
#5 TS=(((viscoelastic OR visco-elastic) AND (detect* OR coagulation OR haemostatic OR hemostatic) AND (system* OR process
OR test OR tests OR analyz* OR analys* OR assay* OR device* OR measurement*)))
#6 TS=(whole blood hemosta* system* OR whole blood haemostat* system*)
#7 #1 OR #2 OR #3 OR #4 OR #5 OR #6
#8 TI=(stabb* OR stab OR shooting OR gunshot* OR blast* OR bomb* OR explosi* OR disaster* OR casualt* OR catastroph* OR
combat* OR battlefield* OR trauma* OR “haemorrhagic shock” OR “hemorrhagic shock” OR “hip fracture” OR “pelvic fracture”)
#9 TS=(trauma* OR “haemorrhagic shock” OR “hemorrhagic shock” OR “hip fracture” OR “pelvic fracture” OR “critical injury”
OR “critical injuries” OR “critically injured” OR “serious injury” OR “serious injuries” OR “seriously injured” OR “severe injury”
OR “severe injuries” OR “severely injured” OR “life-threatening injuries” OR “life-threateningly injured” OR “penetrating injury”
OR “penetrating injuries” OR “blunt injury” OR “multiple injuries” OR “multiply injured” OR polytrauma* OR “hypotensive
resuscitation” OR “hypovolemic shock” OR “hypovolaemic shock” OR coagulopath*)
#10 #8 OR #9
#11 TS=(random* OR “controlled trial” OR “control group” OR “controlled study” OR blind*) OR TI=(randomi* OR trial)
#12 #7 AND #10 AND #11
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